Ouch !!! Yes WDT has dropped .. How ever perc I am still ahead of you in the comp with my re-newed faith.. :-)))
Not material whether it is the OLD WDT or the NEW WDT.. ( Same ... Same.. Same.. )
Going to beat you this year.. :-))
Printable View
It comes a a very great surprise,and embarrassment to me, that at the present time I find myself not "well positioned" in the comp.
This has been compounded by my "lack of faith",not including my largest holding,HBL in the comp.
Yet the comp has some time to run,and I am living in "hope," that I will "rise again" to my proper position, of being ahead of you..............lol.
First bit of activity for 9 days on this thread
https://www.urotoday.com/conference-...w-and-old.html
http://www.sharecafe.com.au/tc.asp?a=AV&ai=44375
Sienna Cancer Diagnostics's IPO will provide an excellent comparison point (performance and valuation) for how PEB is tracking (in real terms) against its 5 year goal of US$100m revenue.
Some very valuable information for those who want to have a better idea of the market for the tests - including the reimbursement process in the US.
https://events.miraqle.com/sdx-ipo/N...eholder-Offer/
Some very stark contrasts between PEB and Sienna.
Guess the market will now have the opportunity to critically assess the differences between the two.
For starters, Sienna is already making profits but only has a market cap of $37m at listing vs PEB's $190m - Sienna has spent a fraction of the hundred million dollars PEB has burnt through so far!
This did catch my eye a few days back Balance.... operating cash flow positive as well I note.
What is interesting, aside from great growth, is how they seem to be reducing their Employee and contractor costs, Administration, R&D expenses, if these had not reduced, they would certainly not have made a profit in the first 6 months... although I haven't read to deeply (yet) into how they managed to achieve this (just know it is quite unusual for an apparent growth company to be spending less and less on these kinds of expenses).
Disclosure: Still holding PEB, but interested in this IPO
Strategy is diametrically opposite to that of PEB - that's why. Read 6.5 onwards in the prospectus.
Not for them the horrendously high overheads of building up sales, marketing and distribution in the US and other jurisdictions (NZ, Oz, Asia and Spain) but use the distribution of established players in the industry, with a FDA product approval.
Notice how low their tests cost versus that of PEB?
The most telling point to me is that Sienna believes they are past early stage and is 'ready for market' with the IPO as opposed to PEB burning through investors' money (with plenty of broken promises and missed milestones along the way).
Anyway, good comparison point with PEB.
For anyone who invested in PEB (based upon the millions of tests opportunities and $100m revenue goal), Sienna's IPO document requires proper reading - very careful proper reading.
Sienna is very realistic about the size of the market and how its tests fit in the industry. No outlandish US$350 a test projection here!
You understand that this test is proposed as an adjunct to cytology only right? And there is nothing in there that I can see that tells us just how much it improves the cytology result.
Siena is just raising a few dollars for 18 months w/cap. Comparing Cxbladder to this unpatented, adjunct only test is just silly as is any comparison of how the two companies should go about establishing their validity and market.